scholarly journals Hemi Retinal Vein Occlusion a Particular Form of Retinal Vein Occlusion

2021 ◽  
Vol 8 (1) ◽  
Author(s):  
Khanaouchi N ◽  
◽  
Mouzarii Y ◽  
Reda K ◽  
Oubaaz A ◽  
...  
Keyword(s):  
Medical History ◽  
Retinal Vein Occlusion ◽  
Fundus Examination ◽  
Cotton Wool ◽  
Slit Lamp ◽  
Retinal Hemorrhages ◽  
Sudden Loss ◽  
Cotton Wool Spots ◽  
Vein Occlusion ◽  
History Of

We report a case of 55-year-old women, with a medical history of hypertension and diabetes, who complained of a sudden loss of vision of her left eye. Her VA was less than 20/200; slit lamp and gonioscopy were unremarkable. Dilated fundus examination had shown an Aspect of HRVO with a Thunder of flame shaped retinal hemorrhages covering the inferior half of the retina, tortuous veins and cotton-wool spots.

scholarly journals A Case of Bilateral Retinal Hemorrhage with Cotton Wool Spot Following Viper Bite

2015 ◽  
Vol 14 (3) ◽  
pp. 297-298
Author(s):  
Subhasis Jana ◽  
Saumen Kumar Chaudhuri ◽  
Purban Ganguly ◽  
Sumi Ghorai
Keyword(s):  
Degradation Products ◽  
Medical Science ◽  
Retinal Hemorrhage ◽  
Fundus Examination ◽  
Cotton Wool ◽  
Retinal Hemorrhages ◽  
Cotton Wool Spots ◽  
Fibrin Degradation Products ◽  
History Of

A 38 years male, admitted in the department of Internal Medicine with a history of snake bite in his left lower leg during agriculture work. He was treated with anti snake venom after admission. He had history of dimness of vision in both eyes. On examination, swelling and subcutaneous hemorrhage was noted in his left leg. His best corrected visual acuity (BCVA) was 6/60 in the both eyes. Fundus examination with 90 D lens and Indirect Ophthalmoscopy of both eyes showed retinal hemorrhage with cotton wool spots. Blood tests revealed increased titers of D-dimer and fibrin degradation products. The patient was followed up regularly at 2 weeks interval and BCVA and Fundus examination was carried out. At the end of 10 weeks, retinal hemorrhages had significantly cleared in both eyes with improvement of vision in both eyes (BCVA of right eye at last follow-up 6/6 and left eye 6/9).Bangladesh Journal of Medical Science Vol.14(3) 2015 p.297-298

scholarly journals injeksi intravitreal triamsinolon pada central retinal vein occlusion

2020 ◽  
Vol 9 (1) ◽  
pp. 119
Author(s):  
Sherly Muchlis ◽  
Weni Helvinda
Keyword(s):  
Plasminogen Activator ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Underlying Disease ◽  
Cotton Wool ◽  
Venous Anastomosis ◽  
Cotton Wool Spots ◽  
Vein Occlusion ◽  
Tissue Plasminogen ◽  
Central Retinal Vein

Central Retinal Vein Occlusion (CRVO) adalah suatu gangguan kondisi pembuluh darah retina yang dapat menyebabkan morbiditas okular yang signifikan dengan gambaran klinis oklusi atau trombosis dari vena sentralis retina mengakibatkan statis vena, edem papil, perdarahan pre retina dan perdarahan difus di lapisan serat saraf serta  cotton wool spots  yang menghasilkan gambaran fundus the blood and thunder. Penatalaksanaan CRVO adalah mengatasi underlying disease dan gejala sisa dari CRVO yaitu edem makula dan neovaskularisasi (NV). Penatalaksanaan edem makula pada CRVO dapat berupa observasi, terapi kortikosteroid, dan intravitreal anti VEGF. Untuk mengatasi NV okular seperti laser fotokoagulasi, dan terapi medikamentosa. Selain itu terdapat beberapa terapi alternatif CRVO yaitu chorioretinal venous anastomosis, tissue plasminogen activator, vitrektomi dan radial optic neurotomy. Dilaporkan seorang wanita usia 59 tahun dengan CRVO OS (tipe iskemik), moderat NPDR OD dan katarak imatur ODS direncanakan injeksi intravitreal triamsinolon OS 4 mg / 0,1 cc di kamar operasi dalam keadaan steril. Tajam penglihatan mata kiri meningkat menjadi 1/60 pada minggu ke-4 dan minggu ke-8 kontrol dan perbaikan pada fundoskopi mata kiri. CRVO biasanya terjadi unilateral, disertai dengan penurunan penglihatan tanpa rasa sakit. Terapi injeksi intravitreal triamsinolon (IVTA) diberikan untuk mengobati edema makula pada CRVO.Kata kunci: central retinal vein ocussion, oklusi vena, IVTA, trombogenesis

scholarly journals Multimodal Imaging of Cotton Wool Spots in Branch Retinal Vein Occlusion

2015 ◽  
Vol 54 (1) ◽  
pp. 48-56 ◽  
Author(s):  
Marion R. Munk ◽  
Gerlinde Matt ◽  
Magdalena Baratsits ◽  
Roman Dunavoelgyi ◽  
Wolfgang Huf ◽  
...  
Keyword(s):  
Retinal Vein Occlusion ◽  
Branch Retinal Vein Occlusion ◽  
Multimodal Imaging ◽  
Cotton Wool ◽  
Cotton Wool Spots ◽  
Vein Occlusion

Cotton Wool Spots after Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Associated with Central Retinal Vein Occlusion

2016 ◽  
Vol 235 (2) ◽  
pp. 106-113 ◽  
Author(s):  
Teruyo Kida ◽  
Akitaka Tsujikawa ◽  
Yuki Muraoka ◽  
Seiyo Harino ◽  
Rie Osaka ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Macular Edema ◽  
Central Retinal Vein Occlusion ◽  
Vascular Endothelial ◽  
Cotton Wool ◽  
Cotton Wool Spots ◽  
Vein Occlusion ◽  
Endothelial Growth Factor ◽  
Central Retinal Vein

Purpose: To report a case series, whereby we encountered a transient increase in retinal cotton wool spots (CWS) following anti-vascular endothelial growth factor (anti-VEGF) therapy for the treatment of macular edema secondary to central retinal vein occlusion (CRVO). Methods: Eighteen eyes were treated with intravitreal aflibercept (IVA), and 5 were treated with intravitreal ranibizumab (IVR). Fundus photographs obtained 1 month after initial IVA or IVR injections were retrospectively evaluated for the presence of CWS. Results: Twenty-one (91.3%) patients had the following systemic diseases: hypertension, diabetes mellitus without retinopathy, dyslipidemia, or chronic renal failure requiring dialysis. One month after treatment, reduced macular edema was observed in 21 (91.3%) eyes. Initial injections facilitated complete resolution in 14 eyes, and CWS gradually became fainter with additional injections. Conclusion: Some eyes with CRVO-related macular edema can show a transient increase in CWS after initial anti-VEGF therapy; however, macular edema, retinal hemorrhage, and visual acuity were improved in almost every case.

scholarly journals Impending Central Retinal Vein Occlusion

2016 ◽  
Vol 78 (3) ◽  
pp. 20
Author(s):  
Michelle Steenbakkers
Keyword(s):  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Vision Loss ◽  
Clinical Manifestations ◽  
Retinal Vessel ◽  
Retinal Hemorrhages ◽  
Blurred Vision ◽  
Prodromal Phase ◽  
Vein Occlusion ◽  
Central Retinal Vein

Central retinal vein occlusion (CRVO) may present with varied clinical manifestations, ranging from mild blurred vision and scattered retinal hemorrhages to severe vision loss, optic nerve swelling, pronounced retinal hemorrhages, collateral retinal vessel formation and neovascularization. Impending CRVO, also known as partial CRVO, is a relatively poorly-defined sub-classification of the CRVO condition. Those affected are either asymptomatic or may complain of mild, often transient episodes of blurring of vision and present with venous dilation and tortuosity but only a few widely scattered flame-shaped retinal hemorrhages. As an impending CRVO may be the prodromal phase of an acute CRVO, this diagnosis requires careful monitoring of the patient for progression. The following case outlines the differential diagnosis, sequelae and inter-professional management of an impending central retinal venous occlusion.

scholarly journals Eye manifestations of COVID-19. Step one

2021 ◽  
Vol 9 (1) ◽  
pp. 34-42
Author(s):  
P.A. Bezdetko
Keyword(s):  
Ganglion Cells ◽  
Severe Pneumonia ◽  
Cotton Wool ◽  
Ocular Complications ◽  
Retinal Hemorrhages ◽  
The Past ◽  
Cotton Wool Spots ◽  
Ocular Surface Diseases ◽  
Plexiform Layers ◽  
Papillomacular Bundle

In the past few months, medical practice has changed faster than in the past few decades. This was due to the coronavirus disease (COVID-19) pandemic. Ophthalmic problems are most significant in patients with severe pneumonia. The exact incidence of conjunctivitis in COVID-19 patients ranges from 0.8 to 31.6 %. Optical coherence tomography demonstrated hyperreflective lesions at the level of ganglion cells and inner plexiform layers, more pronounced in the papillomacular bundle of both eyes. Retinal hemorrhages were found in at least one eye in five patients (9.25 %), cotton wool spots were detected in four people (7.4 %), and drusen was observed in six patients (11.1 %). On examination of the fundus, dilated veins were revealed in 15 patients (27.7 %), tortuous vessels — in 7 individuals (12.9 %). The literature reports describe patients who were diagnosed with COVID-19 after the detection of diplopia and ophthalmoparesis. The incidence of ocular complications in patients of the intensive care units in different studies ranges from 3 to 60 %. The most common manifestations are ocular surface diseases, increased intraocular pressure, and disorders of the anterior and posterior segments.

Risk factors in central retinal vein occlusion: A multi-center case-control study conducted on the Italian population

2021 ◽  
pp. 112067212110644
Author(s):  
Trovato Battagliola Edoardo ◽  
Pacella Fernanda ◽  
Malvasi Mariaelena ◽  
Scalinci Sergio Zaccaria ◽  
Turchetti Paolo ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retinal Vein Occlusion ◽  
Central Retinal Vein Occlusion ◽  
Active Smoking ◽  
Vein Occlusion ◽  
History Of ◽  
Group A ◽  
Group B ◽  
Control Study ◽  
Central Retinal Vein

Purpose To explore the risk factors for central retinal vein occlusion (CRVO) by comparing a large sample of patients with healthy controls. Materials and Methods Multi-center case-control study. The study group includes patients affected by central retinal vein occlusion, confirmed angiographically, aged 50 years old or above (Group A). The control group includes healthy subjects without an history of retinal vein occlusion (Group B). Outcome measures: age, gender, active smoking, presence of uncontrolled arterial hypertension (uHTN), presence of the following comorbidities: diabetes mellitus type II (DMII), chronic liver disease (CLD), chronic kidney disease (CKD), thyroid disease (TD), systemic lupus erythematosus (SLE), hyperhomocystenemia (HHcy), dyslipidemia (DLip), carotid artery disease (CAD), glaucoma, atrial fibrillation (AF), migraine headache (MH), chronic obstructive pulmonary disease (COPD), obstructive sleep apnea syndrome (OSAS), history of myocardial infarction (MI). Odds-ratios were calculated with logistic regression analysis. Results A total of 203 patients (Group A) and 339 controls (Group B). Statistically-significant differences were found for the following variables: age (OR: 1.109 [1.081–1.138], p < .001), active smoking (OR: 2.048 [1.210- 3.466], p < .008), DMII (OR: 4.533 [2.097–9.803], p < .001), HHcy (OR: 4.507 [2.477–10.001 ], p < .001), DLip (OR: 2.255 [1.352–3.762], p  =  .002), CAD (OR: 6.632 [2.944- 14.942], p < .001), glaucoma (OR: 4.656 [2.031–10.673], < .001), OSAS (OR: 1.744 [1.023–2.975], < .041), uHTN (OR: 3.656 [2.247–5.949], < .001). No statistically-significant differences were found for the other variables. Conclusions Older age, active smoking, as well as presence of DMII, HHcy, DLip, CAD, glaucoma, OSAS, and uHTN, all increase the risk for CRVO. A comprehensive assessment of patients with CRVO is paramount. Adequate control of all the aforementioned risk factors is likely of great significance in reducing the incidence of CRVO among the general population, and it likely plays an important role in improving the prognosis following the occlusive event.

The Use of the PFA-100® and Thromboelastograph in Assessing Haemostasis and Drug Efficacy in Essential Thrombocythemia.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4959-4959
Author(s):  
Betty Y.Y. Cheung ◽  
Kiran Parmar ◽  
Ghasem Yadegarfar ◽  
Beverley J. Hunt ◽  
Claire N. Harrison
Keyword(s):  
Platelet Count ◽  
Retinal Vein Occlusion ◽  
Essential Thrombocythemia ◽  
Central Retinal Vein Occlusion ◽  
Clot Strength ◽  
Vein Occlusion ◽  
Increased Risk ◽  
History Of ◽  
Digital Ischaemia ◽  
Central Retinal Vein

Abstract Introduction. Essential thrombocythemia (ET) is associated with an increased risk of thrombosis. Many patients are treated with anti-platelet agents and/or cytoreductive therapy in order to minimise the risk but some still develop thrombotic events. The PFA-100® is an effective near-patient platelet function analyser and the Thromboelastograph (TEG®) Haemostasis Analyser assesses global haemostasis in whole blood. The usefulness of these technologies has not been fully evaluated in ET. Patients and Methods. We compared results from the PFA-100® and TEG® in 25 ET patients and 19 controls. Overall the ET patients comprised 18 females and 7 males, their median age was 55 yrs, median platelet count 423x109/l. Twenty-two were on anti-platelet therapy (21 on 75mg aspirin, 1 on aspirin and clopidogrel). Seventeen patients were receiving cytoreductive therapy (10 hydroxyurea, 2 a-interferon, 4 busulphan and 1 busulphan with anagrelide). Eight patients had previous thrombosis (4 transient ischaemic attacks, 1 stroke, 1 central retinal vein occlusion, 2 multiple events [1 stroke, erythromelalgia and digital ischaemia; 1 central retinal vein occlusion and digital ischaemia]) and 2 had haemorrhagic events. Results. All had normal INR, APTT and fibrinogen levels. Using the PFA-100®, Collagen/ADP closure times were prolonged in 15 (60%) patients compared to normal controls, suggesting platelet dysfunction, which included both patients with previous bleeding episodes. Twenty (91%) patients on aspirin had prolonged Collagen/Epinephrine closure times but for 2 (9%) patients these were within the normal range indicating aspirin-resistance. Both these patients had a history of thrombosis whilst on aspirin alone. Using TEG®, ET patients when compared to controls, took longer to initiate and to reach maximal clot strength (significantly longer R and K times, p=0.001, p=0.012 respectively and smaller angle, p=0.01) but the developed clot had a higher tensile strength (larger MA, p=0.024). There was a positive correlation between fibrinogen levels and MA (r=0.54, p=0.006) as well as APTT with R time (r=0.437, p= 0.029). There was no correlation between platelet count or prior history of thrombosis with any PFA-100® or TEG® variables. Conclusion. Low-dose aspirin had biochemical efficacy as assessed by PFA-100® Collagen/Epinephrine closure times in most but not all ET patients. Further studies are necessary to assess whether Collagen/ADP times can identify those at risk of bleeding. In ET, the TEG® demonstrates slower formation but a higher tensile clot strength than controls. Larger studies are needed to fully evaluate these findings and their clinical relevance.

Sign in / Sign up

Export Citation Format

Share Document